Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Locally Advanced Esophageal Carcinoma Clear all
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
Pamiparib, Temozolomide
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
7
States / cities
Grand Rapids, Michigan • St Louis, Missouri • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced May 22, 2026, 12:16 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Localized Stage I-III Esophageal Cancer, Gastroesophageal Junction Cancer
Interventions
nutritional and functional assessments
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Metastatic Colorectal Carcinoma (mCRC), Advanced Lung Carcinoma, Locally Advanced Hepatocellular Carcinoma
Interventions
Olanzapine, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced May 22, 2026, 12:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
Interventions
Placebo, Regorafenib
Other · Drug
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Urbana, Illinois • Wichita, Kansas • New Orleans, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced May 22, 2026, 12:16 AM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
rubitecan
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions
Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Patritumab Deruxtecan
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
HER2-expressing Cancers
Interventions
ZW49
Drug
Lead sponsor
Zymeworks BC Inc.
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions
ASP546C
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Los Angeles, California • Grand Rapids, Michigan • Lake Success, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced May 22, 2026, 12:16 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Esophageal Cancer
Interventions
18F-FDG (Fluorodeoxyglucose) PET, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
bryostatin 1, paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced May 22, 2026, 12:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2023 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer of the Esophagus
Interventions
Panitumumab, Capecitabine, Oxaliplatin, Radiation Therapy (RT)
Drug · Radiation
Lead sponsor
Brian Czito
Other
Eligibility
18 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced May 22, 2026, 12:16 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
Interventions
Seribantumab
Drug
Lead sponsor
Elevation Oncology
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions
Enzelkitug, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Sarasota, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 22, 2026, 12:16 AM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Drug · Biological
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Sioux City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced May 22, 2026, 12:16 AM EDT
Terminated Phase 3 Interventional
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Esophagectomy
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2012 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Esophageal Carcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Locally Advanced Urothelial Carcinoma, Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Colorectal Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Esophageal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Cutaneous Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration
Other · Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced May 22, 2026, 12:16 AM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Siewert Type 1 GEJ Cancer, Pancreatic Cancer
Interventions
Futibatinib, Pembrolizumab, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Irinotecan
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
Interventions
Esophageal sparing IMRT
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer, Gastroesophageal Junction Carcinoma, Esophageal Adenocarcinoma
Interventions
Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin, Capecitabine
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Goodyear, Arizona • Duarte, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 12:16 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC)
Interventions
177Lu-BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced May 22, 2026, 12:16 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma, Head and Neck Cancer Stage IV, Head and Neck Cancer Stage III, HPV-Related Carcinoma, HPV-Related Malignancy, HPV-Related Squamous Cell Carcinoma
Interventions
IPI-549
Drug
Lead sponsor
Assuntina G. Sacco, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced May 22, 2026, 12:16 AM EDT